Researchers in China have unveiled intriguing findings regarding the influence of gut bacteria on sugar cravings, particularly focusing on the bacterium Bacteroides vulgatus and its production of pantothenate, also known as vitamin B5. The study reveals that these elements can significantly reduce a rodent's preference for sugar. This research highlights the potential connection between gut health and dietary preferences, shedding light on how specific microbes may modulate cravings.
In experiments conducted on mice, the absence of certain bacteria, including Lactobacillus salivarius, L. gasseri, L. johnsonii, and Muribaculaceae, was linked to increased sugar cravings. When researchers introduced these bacteria and vitamin B5 to mice lacking them, there was a noticeable reduction in sugar consumption. This process involves a biochemical cascade that triggers GLP-1, a protein known for its role in controlling blood sugar levels and weight.
The implications of these findings extend to the pharmaceutical realm. Drugs like Ozempic, which are based on semaglutide, mimic GLP-1's action to regulate blood sugar and assist with weight management. However, the study noted that B. vulgatus only reduced sugar cravings in mice lacking the FFAR4 gene. These mice exhibited lower levels of B. vulgatus and pantothenate, which correlated with heightened sugar cravings. Fortunately, the majority of humans possess an intact FFAR4 gene, suggesting that for most people, B. vulgatus and pantothenate may not significantly influence sugar cravings.
The absence of certain bacteria can also lead to cravings for high-fat foods, broadening the scope of this research beyond just sugar. Probiotics, often marketed as dietary supplements to support gut health, remain unregulated by the U.S. Food and Drug Administration (FDA). This lack of regulation means that companies are not mandated to test probiotics on humans or prove their efficacy.
Dr. Pieter Cohen, an internal medicine doctor at Harvard Medical School, has expressed skepticism about the effectiveness of commercial probiotics. His research focuses on supplement safety and he emphasizes the need for caution.
“It is disconnected from any actual evidence in humans that they work,” – Pieter Cohen
Similarly, Dr. Sarkis Mazmanian, a microbiologist at Caltech who specializes in beneficial bacteria, also remains cautious about the claims surrounding commercial probiotics.
“In 2025, I’m still skeptical of these claims,” – Sarkis Mazmanian
Moreover, Dr. Mazmanian notes potential adverse effects associated with B. vulgatus.
“There’s some evidence that B. vulgatus has a dark side,” – Sarkis Mazmanian
Some individuals may experience gastrointestinal issues due to this bacterium, adding complexity to its role in health management. Despite promising results in rodents, there is currently no concrete evidence supporting the efficacy of probiotics in humans for managing sugar cravings.
Leave a Reply